Calculate your potential savings with our ROI Calculator
ROI Calculator
Cell and gene therapies (CAGT) offer groundbreaking approaches for the treatment, prevention, and possible cure of illnesses. These cutting-edge medical treatments offer hope to patients with ailments that are often poorly understood and broadly deemed incurable, including genomic illnesses and cancers.
As per a survey of healthcare professionals, the CAGT industry is projected to have the maximum impact on the pharmaceutical sector. However, the success of CAGT depends on a robust and reliable supply chain, which poses a major logistical challenge for the scientific community.
The vein-to-vein traceability that involves collecting patient cells, transporting them to a facility, processing them, and returning them to the patient requires unyielding coordination.
Additionally, there are challenges between rapid innovation and strict regulatory oversight. For example, developing potency to ensure product integrity is a major hurdle in meeting regulatory standards.
Moreover, for gene therapies, any temperature variations or rough physical handling of samples can jeopardize the therapy’s efficacy and, by extension, patient safety.
In this blog, we will explore how eQMS plays a foundational role in the CAGT industry by automating paper-based processes within a centralized, compliant digital ecosystem, ensuring stringent compliance with regulatory standards.
CAGT gives more importance to fixing or transforming cells and genes to cure, instead of treating diseases. However, commercializing these innovative therapies requires an effective manufacturing strategy and a seamless path from conducting clinical research to delivering treatment to patients.
With the right method, prevailing challenges can be overcome while getting innovative drugs to patients and delivering them quickly. Growth can be achieved by embracing digital solutions that revolutionize how production records are supervised and by ensuring quality. These digital solutions maintain data trails that withstand regulatory scrutiny.
Navigating the complex and dynamic gene therapy regulatory landscape has been a persistent challenge for manufacturers. Ensuring these life-changing therapies successfully pass critical regulatory milestones on the journey to market requires gene therapy producers and their partners to demonstrate both flexibility and agility.
The approval pathways, regulatory and oversight processes, and enforcement of regulatory compliance by both the U.S. FDA and European Medicines Agency are different, yet both agencies share several regulatory principles to achieve the same goal. Sponsors conducting clinical trials worldwide must navigate through both regulatory systems to ensure compliance, minimize delays, and ultimately bring new therapies to market.
Three key regulations form the basis of the CAGT regulatory framework: Good Practice, 21 CFR Part 11 and Annex 11. Collectively, they establish mandatory requirements to validate and protect the integrity of electronic data while ensuring safety when developing cell and gene therapies.
Documenting all materials supports the legal basis for compliance with regulations and provides assurance of accuracy. It provides an organization with the assurance that it has demonstrated compliance, accurately reported its results, and established a strong base for their internal controls.
For Cell and Gene Therapy startups, long-term success depends on forming a robust foundation in compliance, quality, and scalability early on. Fulfilling regulatory mandates is just a small component of the equation. Investors want a guarantee that startups have good processes, forceful controls, operational excellence, and a strong path to sustainable growth.
An electronic Quality Management System can be influential in attaining the following key objectives for the CAGT industry to ensure growth and compliance.
Full traceability is essential in CAGT to ensure the integrity of the product and the safety of patients by ensuring all the individual pieces of the product remain untouched from the time of apheresis (a procedure that employs a specific machine to isolate blood into its different components) until administration. This includes having proper Chain of Identity and Chain of Custody to ensure all transfers are accurate, and each product is kept at the appropriate temperature. This is often accomplished using advanced digital orchestration solutions to connect each patient's cells to their final product.
It is the duty of blood institutes to set up their activities so that quality and safety mandates are met. The implementation of a potent quality management system will contribute to the attainment of this objective. A QMS integrates risk-based thinking in all major aspects of the vein-to-vein transfusion process and includes quality monitoring, which is planned, perpetual, and correctly assessed.
CAGT provides a unified solution to the management of a product's full life cycle in its cloud-based system. With its comprehensive visibility of quality workflows such as document control, corrective and preventive action, and audit management software, Qualityze enables compliance to a wide range of regulations, including FDA and ISO.
Document Control is the creation, maintenance, storage retrieval, and tracking of documents essential for research, production, regulatory compliance, and development in CAGT. Key types of documentation include:
Version control prevents employees and decision-makers from acting on incomplete, old, and missing information across departments, and this has significant financial implications. Document Control process is envisioned to preserve document precision, compliance, traceability, and effectiveness. It ensures that key documents remain reliable, up-to-date, and aligned with administrative standards and regulatory requirements.
Overseeing clinical trial deviations and CAPAs is an intricate but key aspect of clinical trial management. By understanding the causes and effects of deviations, implementing potent management strategies, and espousing best practices, trial sponsors and managers can reduce the risks linked to deviations and ensure the triumph of their trials.
Root cause analysis (RCA) allows medical device teams to think proactively about a high-risk event, why it transpired, and what can be done to stop it. These goals directly mirror corrective and preventive actions, and they’re named as the fourth step of the root cause analysis process. CAPA and RCA are both triggered by nonconformance and encourage continuous improvement of quality processes.
Preventing the reappearance of deviations and nonconformances in high-risk environments entails a strong Quality Management System that goes beyond control to complete enhancement. Effective prevention of deviations depends on detailed RCA and evidence-led corrective actions.
Supplier Quality Management can help businesses manage critical raw materials and vendors and share information effortlessly with suppliers by incorporating audit, risk, change, document management, and other QMS capabilities into operations. This secure, cloud-driven solution can address concerns, take corrective actions, and inculcate best practices in supplier relationships, ensuring quality, compliance, and readiness.
Supplier qualification and audits are important processes in the Supplier and Material Quality Management system used to identify if a supplier regularly meets quality, regulatory and technical requirements. They include an initial supplier assessment, ongoing supplier performance monitoring, and approval of workflows. This is important to avoid production stoppage in GMP environments.
To sustain robust biologics supply chains, especially for complex products such as monoclonal antibodies, consistent, quality-by-design (QbD) principles are essential in supplier management and in the proper management of the quality of materials that make up the final product. Biological products exhibit high variability because they are derived from living systems, making it imperative to control factors such as raw materials, cell culture media, and single-use technologies to ensure product quality.
In CAGT operations, risk-based approaches involve allocating resources to the highest-risk areas associated with patient safety, product quality, and data integrity, rather than universal compliance. This very forward-looking strategy is vital in a complex and highly regulated CAGT environment where manufacturing processes are frequently decentralized or customized.
Identifying the risks in products and processes associated with CAGT operations is a pre-emptive approach to management and is referred to as Quality by Design. Identifying product and process hazards at an early stage helps ensure patient safety, ensures the products produced meet the required quality standards, and prevents costly errors during manufacturing. Given that in CAGT there are living cells, complex processes, and often open unit operations, identifying risks at an early stage is preferable, ideally during the process development phase.
Qualityze provides access to real-time supplier data and proactively mitigates risk through automated risk identification and structured CAPA processes. By integrating Environmental Health and Safety (EHS) and Quality Systems data, Qualityze allows manufacturers to proactively identify potential quality and compliance deviations before they impact patient safety.
Thorough preparation is needed for FDA/EMA inspections, and deploying an effective QMS is imperative. Key measures include conducting mock audits regularly and staff training. For instance, a company must have appropriate documentation ready, perform gap analyses, control how information is provided to auditors during audits, and have an established inspection management team.
A foundation for audit readiness and inspection management is key to a complete and accurate audit trail. Auditing requirements exist in different healthcare-related environments regulated by GMP, GxP, and/or the FDA. Each record that is created, modified, or deleted must have a secured, computer-generated, time-stamped record of "who, what, when, why" it was created, modified, or deleted.
Continuous monitoring of controls through real-time visibility is accomplished through automated dashboards. These dashboards provide relevant information on compliance, such as training records, documentation, and risk data. By employing Qualityze, organizations will be inspection-ready and gain ability to identify issues through better deviation detection.
To maintain data integrity, it is vital to embed ALCOA+ principles (attribution, legibility, contemporaneity, accuracy, originality, etc.) into an automated process with a proper data lifecycle from inception to archive. Compliance automation ensures that all data is stored securely through automated processes that comply with regulations. Audit trails, digital signatures, and time stamps synchronized with other electronic systems are examples of how compliance automation reduces the risk of unauthorized data modification.
By automating all aspects of data entry, validation, and reporting, businesses will reduce manual and transcription errors and erase inconsistencies across all entries. The most effective ways to achieve this include automated data capture via barcodes, centrally controlled user access rights, automated detection of anomalous activity using artificial intelligence, and the establishment of a digital audit trail for every transaction within the organization.
Automating compliance workflows streamline tasks such as data collection, risk assessment, and reporting, ensuring accurate information and reducing the risk of manual errors. Manual auditing processes are transformed into ongoing activities, providing those responsible with a dashboard and notifications to alert staff before events that cause noncompliance.
Predictive insights integrated with AI tools is a gamechanger for operational excellence, enabling businesses to identify problems and opportunities before they occur. Businesses can expand in ways that last longer and gain an edge over competitors by using predictive models to optimize performance. Predictive analytics will remain a key part of their efforts to improve operations.
Leveraging AI for continuous improvement is moving from predictive maintenance toward independent, real-time quality control and generative, data-led decision-making. Integrating AI with lean practices to reduce waste, employing computer vision for precise defect detection, and using predictive analytics to cut maintenance costs are some of the key trends.
The Salesforce-native platform has been built to provide a scalable infrastructure that supports the many complexities of the Cell and Gene Therapy (CAGT) space by leveraging cloud-native principles, focused data models, and unified AI. By 2026, CAGT Companies will be able to use these platforms to better manage their complex patient journeys, regulatory compliance, and the scaling of clinical supply chains from research to commercialization.
Collaboration within the Cell and Gene Therapy (CAGT) ecosystem is essential for transforming inherently complicated, patient-specific processes to commercially successful, scalable outcomes. Effective collaboration enables teams involved in Quality Assurance (QA), Quality Control (QC), Manufacturing and Regulatory Affairs, and external partners to work together to ensure digital transparency and an aligned understanding of GxP requirements.
CAGT must effectively combine their scientific advancements with robust operational strategies to manage the transition from clinical to commercial production. Examples of industry best practices include the use of digital technology, development of scalable Quality Management Systems (QMS) early in the process, and ongoing use of objective, data-based monitoring.
Qualityze EQMS offers applications to cell and gene therapy (CAGT) organizations that are specific to the CAGT industry, regulatory compliance, and AI-driven insights. Essentially, providing CAGT organizations with greater speed (i.e., ROI) through automated workflows for quality operations. Qualityze EQMS enables organizations to develop an end-to-end quality operation traceability system through:
Module Development - The application is configurable for regulated industries, including biotechnology and life science, and offers the following modules: Corrective and Preventive Action, Document Control, Change Management, Audit Management, Training Management, and more.
Regulatory Compliance - Application developed with global standards in mind, enabling organizations to be prepared for regulatory audits and minimize non-compliance risk.
Closed-loop Quality - Facilitate the integration of deviations, subsequent investigations, and CAPAs into a single quality management system.
Author
Qualityze Editorial is the unified voice of Qualityze, sharing expert insights on quality excellence, regulatory compliance, and enterprise digitalization. Backed by deep industry expertise, our content empowers life sciences and regulated organizations to navigate complex regulations, optimize quality systems, and achieve operational excellence.
